Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia
Abstract Introduction Ventilator-associated pneumonia (VAP) is a prominent cause of morbidity and mortality in intensive care unit patients. Ceftolozane/tazobactam could be a cost-effective treatment option prior to culture test result for treatment of VAP. This study aims to evaluate the cost-effec...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2025-10-01
|
| Serier: | Cost Effectiveness and Resource Allocation |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s12962-025-00658-0 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|